RecruitingPhase 3NCT06058442
The Pancreatic Enzymes After Gastrectomy Trial
Sponsor
University of Leipzig
Enrollment
188 participants
Start Date
Jan 24, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This trial evaluates the effects (e.g. on quality of life, weight) of NORTASE® compared to standard care of patients who have undergone gastrectomy.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called NORTASE® and a drug called Placebo for people with gastrectomy. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNORTASE®
10-15 capsules of NORTASE® per day - over 6 months
DRUGPlacebo
10-15 capsules of placebo per day - over 6 months
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06058442
Related Trials
Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve Gastrectomy
NCT068108821 location
The UGIRA International Registry for RAMIG for Gastric Cancer
NCT075174321 location
How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer
NCT069827681 location
Reduced Port Laparoscopic Gastrectomy for Gastric Cancer
NCT042954731 location
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
NCT060287372 locations